[S35] The Path for Bacteriophage as the Pharmaceutical Products in Japan

5:30 PM - 5:50 PM JST(8:30 AM - 8:50 AM UTC)

[S35-3] Potential of phage therapy against highly virulent CA-MRSA strains

○Hidemasa Nakaminami¹ (1. Sch. Pharm., Tokyo Univ. Pharm. Life Sci.)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.